Abbvie launching another upadacitinib phase 3 trial w/essentially zero preliinary data I personally love this strategy; I think Phase 2's are an expensive waste of time Better to go big and answer the question? COI: I participate in SELECT-GCA #ACR22 @RheumNow #Vasculitis22 https://t.co/fSs3xt8baA